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ORIGINAL INVESTIGATION
High glucose-induced hyperosmolarity 
contributes to COX-2 expression 
and angiogenesis: implications for diabetic 
retinopathy
Rosalinda Madonna1,2, Gaia Giovannelli3, Pamela Confalone1, Francesca Vera Renna1, Yong‑Jian Geng2 
and Raffaele De Caterina1* 
Abstract 
Background: We tested the hypothesis that glucose‑induced hyperosmolarity, occurring in diabetic hyperglycemia, 
promotes retinal angiogenesis, and that interference with osmolarity signaling ameliorates excessive angiogenesis 
and retinopathy in vitro and in vivo.
Methods and Results: We incubated human aortic (HAECs) and dermal microvascular endothelial cells (HMVECs) 
with glucose or mannitol for 24 h and tested them for protein levels and in vitro angiogenesis. We used the Ins2 Akita 
mice as a model of type 1 diabetes to test the in vivo relevance of in vitro observations. Compared to incubations 
with normal (5 mmol/L) glucose concentrations, cells exposed to both high glucose and high mannitol (at 30.5 or 
50.5 mmol/L) increased expression of the water channel aquaporin‑1 (AQP1) and cyclooxygenase (COX)‑2. This was 
preceded by increased activity of the osmolarity‑sensitive transcription factor Tonicity enhancer binding protein 
(TonEBP), and enhanced endothelial migration and tubulization in Matrigel, reverted by treatment with AQP1 and 
TonEBP siRNA. Retinas of Ins2 Akita mice showed increased levels of AQP1 and COX‑2, as well as angiogenesis, all 
reverted by AQP1 siRNA intravitreal injections.
Conclusions: Glucose‑related hyperosmolarity seems to be able to promote angiogenesis and retinopathy through 
activation of TonEBP and possibly increasing expression of AQP1 and COX‑2. Osmolarity signaling may be a target for 
therapy.
Keywords: Glucose, Diabetes, Hyperosmolarity, Cyclooxygenase‑2, Angiogenesis, Microangiopathy, Diabetic 
retinopathy
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Background
Hyperglycemia can cause diabetic micro- [1] and macro-
vascular complications [2] by triggering oxidative stress 
[3, 4], forming advanced glycation end products (AGEs) 
[4, 5], increasing the flux of glucose to sorbitol through 
the polyol and hexosamine pathways [3], activating 
protein kinase C (PKC) [6], and provoking inflammation 
[7] (reviewed in [8]). Diabetic microvascular disease is 
pathologically characterized by excessive vessel growth 
and increased vessel permeability [9, 10].
Hyperglycemia has been reported to increase the 
endothelial expression of the proinflammatory proteins 
intercellular adhesion molecule (ICAM)-1 and vascular 
cell adhesion molecule (VCAM)-1, and to decrease pro-
duction of nitric oxide, all through activation of the water 
channel protein aquaporin (AQP)1 [11]. Hyperosmotic 
stress inevitably accompanies hyperglycemia, and may 
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therefore contribute to some aspects of hyperglycemia-
induced vascular injury.
Similarly to VCAM-1 and ICAM-1, cyclooxygenase 
(COX)-2 participates in inflammation [12] and angiogen-
esis [13, 14]. Induced by cytokines, mitogens and endo-
toxin [12], COX-2 regulates the expression and activity of 
matrix metalloproteinase (MMP)-9 [15], which degrades 
extracellular matrix and promotes endothelial cell migra-
tion and vessel sprouting [16]. Endothelial COX-2 has 
been implicated in angiogenesis (mostly in the context 
of tumorigenesis, reviewed in [17]), as well as in prolif-
erative diabetic retinopathy [18], characterized by exces-
sive angiogenesis [19–21]. COX-2 is expressed in human 
monocytes and macrophages, as well as human endothe-
lial cells [22] exposed to high glucose [7].
Against this background, we therefore examined 
whether hyperosmotic stress, at levels attainable in dia-
betes, induces COX-2 expression in human micro- and 
macrovascular endothelial cells. We then analyzed the 
functional impact of hyperosmotic stress and COX-2 
expression on angiogenesis and explored underlying 
mechanisms, particularly with regard to the involvement 
of water channels and associated signaling molecules. 
Finally, we investigated the in  vivo implications of such 
findings for diabetic retinopathy in a mouse model.
Methods
Materials
d-glucose, D-mannitol and l-glucose (these two latter 
devoid of metabolic activities and used as a purely hyper-
osmolar controls), saccharose, and sodium chloride, were 
purchased from Sigma (St. Louis, MO, USA). The selec-
tive COX-2 inhibitor NS-398 was purchased from Cal-
biochem (Gibbstown, NJ, USA).
Animal care
Male C57BL/6 mice (body weight: 15 ± 4 g, age: 1 year; 
n  =  21) and male D2.B6-Ins2 Akita diabetic mice, a 
model of type 1 diabetes developing retinal angiogen-
esis [23, 24] (body weight: 11 ±  2 g, n =  21) were pur-
chased from The Jackson Laboratories (Bar Harbor, ME, 
USA). All procedures were approved by our Institutional 
Ethics Committee for Animal Research. Investigations 
conformed to the Principles of Laboratory Animal Care 
formulated by the National Society for Medical Research 
and the Guide for the Care and Use of Laboratory Ani-
mals [NIH Publication 86–23, 1985 revision].
Cell cultures
Subconfluent human aortic endothelial cells (HAECs) 
and human microvascular endothelial cells (HMVECs) 
at passage 3 were synchronized by starvation in Endothe-
lial Basal Medium (EBM, Clonetics, Baltimore, MD, 
USA) for 24  h, then incubated with control d-glucose 
concentration (5.5  mmol/L, control and 285  mOsm/L), 
high glucose (HG: 30.5  mmol/L and 385 mOsm/L or 
50.5  mmol/L and 460  mOsm/L), high mannitol (HM: 
5.5  mmol/L glucose +  25  mmol/L and 385  mOsm/L or 
45 mmol/L mannitol and 385 mOsm/L), for 24 or 72 h. In 
some experiments, cells were also incubated with l-glu-
cose at equimolar concentrations, saccharose or sodium 
chloride, as further osmotic controls, in the presence or 
absence of 1–10 μg/mL NS-398.
Cell viability after treatments was assessed by cell mor-
phology and cell count at phase-contrast microscopy, 
Trypan blue exclusion, and total protein content.
Immunoblotting
Total proteins from retinas of wild-type C57BL/6 male 
mice and sex/age matched D2.B6-Ins2 Akita diabetic mice, 
or from HMVECs and HAECs were isolated, electroblot-
ted, and incubated with the following primary and sec-
ondary antibodies: (1) goat polyclonal anti-COX-2 (cat. N° 
sc-1747, dilution 1:500, Santa Cruz Biotechnologies, Santa 
Cruz, CA USA), secondary antibody mouse anti-goat IgG-
HRP (cat. N° sc-2354, dilution 1:5000, Santa Cruz); (2) 
mouse monoclonal anti-AQP1 (cat. N° sc-55466, dilution 
1:600, Santa Cruz), secondary antibody goat anti-mouse 
IgG-HRP (cat. N° sc-2005, dilution 1:5000, Santa Cruz); 
(3) mouse monoclonal anti-β-actin (cat. N° A5441, dilu-
tion 1:5000, Sigma, St. Louis, MO, USA), secondary anti-
body goat anti-mouse IgG-HRP (cat. N° sc-2005, dilution 
1:5000, Santa Cruz); (4) rabbit polyclonal anti-TonEBP 
(cat. N° sc-13035, dilution 1:500, Santa Cruz), secondary 
antibody goat anti-rabbit IgG-HRP (cat. N° sc-12304, dilu-
tion 1:10000, Santa Cruz), as previously described [25].
Transfection of AQP1 and tonicity enhancer binding 
protein (TonEBP)/nuclear factor of activated T cells (NFAT)5 
siRNA
A pool of three different small interfering RNA (siRNA) 
oligonucleotides to each target (AQP1 and TonEBP/
NFAT5), as well as scrambled control siRNA were incu-
bated with cells (2 × 105/well) in transfection medium, as 
previously described [26]. After 24 h, fresh medium was 
added with or without HG (30.5 or 50.5 mmol/L), or HM 
(5.5 mmol/L glucose + 25 or 45 mmol/L mannitol), incu-
bated for an additional 24 h, then subjected to Western 
analysis of COX-2, AQP1, TonEBP/NFAT5 and β-actin.
Tube formation assays
Tube formation assays were performed as previously 
described [26]. Before the assay, cells were incubated 
in low serum (2.5  %) endothelial basal medium (EBM, 
BD Biosciences) without endothelial growth factors, 
with concentrations of control glucose (5.5  mmol/L, 
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control), high glucose (30.5 or 50.5  mmol/l), high man-
nitol (5.5  mmol/L glucose  +  25 or 45  mmol/L manni-
tol) for 24 h, in the presence or absence of the selective 
cyclooxygenase(COX)-2 inhibitor NS-398 at 1–10  μg/
mL. In the assay testing the effect of siRNA to aquaporin 
(AQP)1 or TonEBP, cells were pretreated with high glu-
cose or high mannitol for 24 h. At the end of incubations, 
cells were gently detached with 0.25  % trypsin–EDTA; 
trypsinized cells were then collected, counted and plated 
on Matrigel (at a density of 2 × 105 cells/50 μL Matrigel) 
for a further 16 h, in the presence or absence of control 
glucose, high glucose, high mannitol, with or without 
NS-398, or siRNA to AQP1 or TonEBP.
Cell migration assay
Cell migration was measured using the CytoSelect™ cell 
migration assay (Cell Biolabs, San Diego, CA, USA), 
according to the manufacturer’s instructions. Following 
a 24  h starvation period in 2  % fetal calf serum (FCS)/
endothelial cell growth medium (EGM), cells were resus-
pended at 4  ×  105 cells/mL in EGM and then placed 
in a separate well of a 96-well feeder tray containing 
150  μL of migration media (EGM with control glucose 
concentration (5.5  mmol/L, control), high glucose (HG 
30.5  mmol/L) or high mannitol (HM HM, 5.5  mmol/L 
glucose + 25 mmol/L mannitol)). One hundred and fifty 
microliters of assay controls, consisting of EGM supple-
mented with 10 % FCS (positive control) and basal EGM 
(negative control), were also tested in triplicate.
Electrophoretic mobility gel shift assay
Nuclear proteins were extracted from treated or untreated 
endothelial cells and subjected to electrophoretic mobil-
ity gel shift assay, as previously described [25]. Double-
stranded synthetic oligonucleotides of the nuclear factor 
(NF)-κB motif (5′-AGT TGA GGG GAC TTT CCC AGG 
C-3′ and 5′-CCT GGG AAA GTC CCC TCA ACT-3′) 
or of the Tonicity enhancer element (5′-GGT TTC TCC 
ACC TTT TCC GCT G-3′) were labeled with [γ-32P]ATP.
Immunoblotting of TonEBP
15 µg of nuclear extracts used for EMSA and of cytosolic 
extracts were electroblotted and incubated with either a 
primary rabbit polyclonal anti-TonEBP (cat. N° sc-13035, 
dilution 1:500, Santa Cruz), secondary antibody goat 
anti-rabbit IgG-HRP (cat. N° sc-12304, dilution 1:10,000, 
Santa Cruz); or an anti-lamin B antibody (Santa Cruz), as 
previously described [25].
Preparation of transit TKO‑siRNA complexes 
and intravitreal injections of non‑viral siRNA
Non-viral siRNA delivery into the mouse retina in  vivo 
was done using a modified version of published methods 
[27]. For monitoring transfection efficacy we used 
scrambled siRNA conjugated with a Cy3 fluorochrome 
provided by Mirus (Mirus Bio, Madison, WI, USA). 
Accordingly, 1.33 μL (25 nM) of Cy3-conjugated scram-
bled siRNA or Cy3-conjugated AQP1-siRNA (Ambion) 
were combined with 0.5 μL of Transit-TKO (Mirus) in a 
final volume 10 μL sterile H2O, and incubated for 30 min 
at room temperature. Wild-type C57BL/6 mice and age-
sex matched D2.B6-Ins2 Akita diabetic mice were anes-
thetized by intraperitoneal injection of ketanest/xylazine 
(ketanest, 100–125  mg/kg; xylazine, 10–12.5  mg/kg). 
Intravitreal injections of phosphate-buffered saline (PBS, 
sham group, N = 7 wild-type C57BL/6 mice and N = 7 
D2.B6-Ins2 Akita mice), or scrambled-siRNA (N  =  7 
wild-type C57BL/6 mice and N  =  7 D2.B6-Ins2 Akita 
mice), or AQP1-siRNA (N = 7 wild-type C57BL/6 mice 
and N = 7 D2.B6-Ins2 Akita mice) were performed under 
a dissecting microscope with a 32 gauge needle attached 
to a 5 μL glass syringe (Hamilton, Reno, NV, USA). The 
needle was positioned 1  mm posterior to the limbus, 
where 5 μL of the solution were slowly (in 3–5 s) injected 
into the vitreous chamber of the eye. Injections were 
repeated after 72 h and 1 week from the first injection.
Tissue preparation and histological evaluation of vessel 
density
After the induction of anesthesia, retinas from D2.B6-
Ins2 Akita diabetic mice and age/sex-matched C57/
BL6 control mice were removed, embedded in optimal-
cutting-temperature (OCT) medium, frozen on dry ice, 
and stored at −70  °C until sectioning. For immunofluo-
rescence staining, 5 μm thick sagittal and frontal cryosec-
tions were obtained by using a sliding cryotome. These 
sections were permeabilized, blocked for 30 min in PBS 
containing 1 % bovine serum albumin, and incubated for 
1 h at 4 °C with purified primary antibody anti-CD31 or 
Cy3-conjugated anti-α-smooth muscle actin (ASMA). A 
non-immune IgG (Becton, Dickinson and Co., Franklin 
Lakes, New Jersey, USA) was used as the isotype control. 
After washing with PBS, retinal sections stained with 
anti-CD31 antibody were incubated with phycoerythrin 
(PE)-conjugated secondary antibody, washed, mounted, 
and viewed with an immunofluorescence microscope. 
Sections were counterstained with 4′, 6-diamidino-
2-phenylindole (DAPI) to identify nuclei. For immuno-
histochemistry, retinas were embedded in five separate 
paraffin blocks. Paraffin-embedded limb sections were 
deparaffinized, rehydrated, and stained with a primary 
antibody against CD31. Sections were counterstained 
with hematoxylin and eosin for structural analysis and to 
identify nuclei. Arterioles and capillaries were counted in 
a blinded manner in five randomly selected fields at 10× 
magnification. Vascular images were captured by using 
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an inverted light microscope (Olympus IX71), and ana-
lyzed by using the Image-J software (Media Cybernetics, 
Rockville, MD, USA). Vessel density was expressed as the 
number of arterioles or capillaries per mm2.
Statistical analysis
Two-group comparisons were performed by the Stu-
dent’s t test for unpaired values. Comparisons of means 
of ≥3 groups were performed by analysis of variance 
(ANOVA), and the existence of individual differences, in 
case of significant F-values at ANOVA, tested by Schef-
fé’s multiple contrasts.
Results
High glucose induces COX‑2 expression in human 
endothelial cells through a hyperosmolar mechanism
Both short-term and longer-term exposure to high con-
centrations of glucose or mannitol, increased the expres-
sion of COX-2 protein, as shown by Western analysis 
(Fig.  1a–g). Similar results were obtained by incubating 
HAECs and HMVECs with l-glucose and NaCl at equi-
molar concentrations (30.5 mmol/L), as a further osmotic 
controls (Fig. 1h–i).
AQP1 mediates high glucose‑induced COX‑2 expression 
in endothelial cells
Since AQP1 regulates responses to hyperosmolar-
ity in endothelial cells [28], we tested whether AQP1 is 
involved in hyperosmolarity-induced COX-2 expression. 
We used targeted disruption of AQP1 gene expression 
by siRNA technology, with 3 different siRNA species, to 
specifically block AQP1. AQP1 siRNA did not affect cell 
morphology or cell proliferation (Fig. 2a), but triggered a 
substantial (80 %) reduction in AQP1 protein expression 
(Fig.  2b). By contrast, serving as a sequence-unrelated 
control, scrambled siRNA did not exert any detectable 
effect. Proteins from AQP1 siRNA-transfected cells were 
then probed for COX-2 abundance. COX-2 expression 
in high glucose- and high mannitol-treated cells was 
substantially suppressed after transfection with siRNA 
against AQP1 (Fig.  2c–d). Taken together, these results 
showed that hyperosmolarity caused by exposure to high 
glucose or mannitol induces COX-2 expression through 
the activation of AQP1.
High glucose promotes angiogenesis 
through hyperosmolarity‑induced expression of COX‑2 
and its transcription factor TonEBP/NFAT5
COX-2 is involved in human angiogenesis, although 
with mechanisms still incompletely understood [29]. To 
explore the involvement of hyperosmolarity in COX-
2-induced angiogenesis, we seeded cells on Matrigel 
after incubation with high glucose or high mannitol in 
the presence or absence of siRNA against AQP1 or the 
COX-2 inhibitor NS-398. In this functional assay of angi-
ogenesis, HAECs were treated with endothelial growth 
factor (EGF) as positive control for tubulization. EGF 
did induce tubule formation, and high glucose or high 
mannitol produced the highest number of network for-
mations. Treatment with siRNA against AQP1 strongly 
reduced the number of these structures (Fig.  3A, C), 
while NS-398 reduced them to a lesser extent (Fig. 3B). 
TonEBP, also called nuclear factor of activated T cells 
(NFAT)-5, is a master transcription factor of genes 
responsive to hypertonic stress [30–32], TonEBP/NFAT5 
siRNA did not affect cell morphology or cell prolifera-
tion (Fig.  3D), but triggered a substantial (80  %) reduc-
tion in TonEBP/NFAT5 protein expression (Fig. 3D). By 
contrast, serving as a sequence-unrelated control, scram-
bled siRNA did not exert any detectable effect. TonEBP/
NFAT5 silencing drastically decreased the network 
number and area formed by HAECs seeded in Matrigel, 
compared with those obtained from glucose and manni-
tol-treated cells (Fig. 3E). Cell migration induced by high 
glucose or high mannitol in a modified Boyden cham-
ber system was also quantified with a fluorimetric assay. 
Migration of TonEBP/NFAT5-deficient endothelial cells 
towards high glucose and high mannitol was significantly 
inhibited (Fig. 3F), indicating a role of TonEBP/NFAT5 in 
mediating hyperosmolarity-induced endothelial migra-
tion and angiogenesis. TonEBP/NFAT5 expression and 
binding activity was increased in cells exposed to high 
glucose and mannitol (Fig.  4a–d), and siRNA against 
TonEBP/NFAT5 24 h prevented the hypertonic induction 
of TonEBP/NFAT5 (Fig. 4a) and COX-2 proteins (Fig. 5a), 
indicating that TonEBP/NFAT5 expression and activity 
are required for the hyperosmolarity induction of COX-
2. Taken together, these results showed that hyperosmo-
larity contributes to the stimulatory effect of COX-2 on 
endothelial angiogenesis mostly through the activation of 
upstream and downstream mediators of hyperosmolarity, 
such as AQP1 and TonEBP/NFAT5, respectively.
The promoter region of the COX-2 gene also con-
tains consensus sequences for NF-κB [33–36], and high 
glucose induces the expression of some genes also by 
activating NF-κB [33, 37]. In order to analyze the con-
tribution of NF-κB to the hyperosmotic stress-induced 
expression of COX-2, we performed EMSA using NF-κB 
binding probe and nuclear extracts from osmotically 
stressed HAECs for 1–24 h. We found low, but detectable 
amounts of NF-κB DNA binding activities in unstimu-
lated cells. After treatment with high glucose (1 and 3 h) 
and TNF-α (up to 24 h), but not with high mannitol or 
sodium chloride, we observed a time-dependent increase 
in NF-κB DNA-binding activity, suggesting that this tran-
scription factor can cooperate to the expression of the 
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COX-2 gene by high glucose, but not in response to high 
glucose-related hyperosmotic stress (Fig. 5b–c).
Retinas of D2.B6‑Ins2 Akita diabetic mice exhibit high 
levels of hyperosmolarity‑enhanced COX‑2 expression 
and angiogenesis
CD31 (a marker of angiogenesis) and α-smooth muscle 
actin (ASMA, a marker of arteriogenesis), along with 
COX-2 and AQP1 were examined in retinas of D2.B6-
Ins2 Akita diabetic mice and sex-age matched C57BL/6 
non-diabetic controls treated with or without siRNAs to 
AQP1. We detected low-level CD31 (Fig. 6a) and ASMA 
immunoreactivities (Fig. 7a–d) in WT mice. However, a 
significant vessel staining for CD31 (Fig. 6b) and ASMA 
(Fig. 7g–l) were apparent in retinas of D2.B6-Ins2 Akita 
mice, mostly in the inner plexiform layer (IPL) and Outer 
plexiform layer (OPL). Retinas in diabetic mice also 
showed increased expression of AQP1 and a significant 
upregulation of COX-2 at the protein level (Fig.  6d–e). 
AQP1 in vivo silencing drastically decreased the number 
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Fig. 1 The effect of high glucose and high mannitol on COX‑2 expression in endothelial cells. Immunoblotting with an antibody against COX‑2 of 
proteins extracted from serum‑starved subconfluent human aortic endothelial cells (HAECs) incubated with control D‑glucose (5.5 mmol/L, con‑
trol), high glucose (HG, 30.5 or 50.5 mmol/L), high mannitol (HM, 5.5 mmol/L glucose + 25 or 45 mmol/L mannitol) for 24 h (a, b) and for 3 days (c, 
d). After COX‑2 analyses, proteins were stripped and restained with an anti‑β‑actin antibody. Lipopolysaccharide (LPS, 1 μg/mL) was used as positive 
control for COX‑2 expression (a, d). e, f Immunoblotting with an antibody against COX‑2 of proteins extracted from serum‑starved subconfluent 
human microvascular endothelial cells (HMVECs) incubated with stimuli (12.5 and 25 mmol/L glucose or mannitol) for 3 days. Representative immu‑
noblots are shown. The results of scanning densitometry (n = 3 independent experiments) are expressed as arbitrary units in panel g. Columns and 
bars represent the mean ± SD (*, P < 0.05 vs control cells; **, P < 0.01 vs control cells). Equal loading/equal protein transfers were verified by protein 
band detection with the anti‑β‑actin antibody. h, i The effect of high D‑glucose, high l‑glucose, high mannitol and NaCl on COX‑2 expression in 
endothelial cells. Immunoblotting with an antibody against COX‑2 of proteins extracted from serum‑starved subconfluent human aortic endothe‑
lial cells (HAECs) incubated with control glucose concentration (5.5 mmol/L, control), high glucose (30.5 mmol/L), high mannitol (5.5 mmol/L 
glucose + 25 mmol/L mannitol), or sodium chloride (30.5 mmol/L), for 24 h. After COX‑2 analyses, proteins were stripped and restained with an 
anti‑β‑actin antibody. Representative immunoblots from three different experiments are shown. i Columns and bars represent the mean ± SD of 
scanning densitometry of panel H (*, P < 0.05 vs control cells; **, P < 0.01 vs control cells)
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of ASMA-positive vascular structures (Fig.  7e–f, m–n) 
and the expression of AQP1 and COX-2 (Fig.  8a, b), in 
D2.B6-Ins2 Akita mice.
Discussion
Clinical consequences of type-1 diabetes result from 
the combination of a number of different factors, 
ranging from acidosis to metabolic changes, to bio-
physical derangements, such as hyperosmotic stress. Pre-
vious research has mostly focused on metabolic disorders 
induced by hyperglycemia and the underlying signaling 
pathways. Several lines of evidence presented here how-
ever indicate that a substantial contribution to the induc-
tion of vascular disease is given by the hyperosmolar 
stress related to hyperglycemia. We show here that con-
centrations of glucose attainable in diabetes induce 
COX-2 in human endothelial cells through an AQP1-
dependent hyperosmolar mechanism and, through 
this mechanism, promote angiogenesis. Specifically, 
in diabetic Ins2Akita mice, retinal COX-2 and AQP1 
are upregulated concomitant with increased angiogen-
esis, suggesting the relevance of our observations in an 
in vivo setting where hyperglycemia is the main driver of 
microvascular disease. Finally, hyperosmolarity, through 
an AQP1-dependent mechanism appears to be causally 
involved in angiogenesis in vivo, and interruption of the 
AQP1 axis mitigates in  vivo increased angiogenesis in 
response to high glucose.
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Fig. 2 The effect of siRNA to AQP1 on COX‑2 expression in endothelial cells exposed to high glucose and high mannitol. Serum‑starved HAECs 
were transfected with Cy5‑coniugated‑siRNA to AQP1 or non‑coniugated‑siRNA to a scrambled sequence for 24 h and then treated with stimuli for 
24 h. At the end of treatments, transfection efficiency was checked by observing the plates under fluorescence microscopy (a), while AQP1 gene 
knockdown efficiency was detected at the protein level by Western analysis (b). Protein expression for COX‑2 was detected by Western analysis, 
with β‑actin serving as a loading control (c). LPS (1 μg/mL) and tumor necrosis factor (TNF)‑α (10 ng/mL) were here used as positive controls for the 
expression of COX‑2. Representative blots (c) are shown. The results of scanning densitometry (n = 3 independent experiments) are expressed as 
arbitrary units in panel d, where columns and bars represent the mean ± SD (**, P < 0.01 mannitol‑ or glucose‑treated vs control HAECs; §, P < 0.05 
vs without AQP1‑siRNA)
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This report expands our previous findings that 
hyperosmotic stress induces endothelial ICAM-1 and 
VCAM-1 expression [11] by showing the involvement 
of COX-2-dependent pathological phenomena. The cur-
rent findings provide evidence that hyperosmolarity is a 
biophysical mechanism through which excessive angio-
genesis may occur in diabetes. Additionally, our findings 
detail part of the molecular signaling through which 
hyperosmolarity promotes such effects.
The involvement of AQP1 in hyperosmolarity-induced 
endothelial tubulization and angiogenesis [38–41] is 
of biological importance. AQP1 is a water channel pro-
tein widely expressed in vascular endothelial cells, 
which, when activated, increases cell membrane water 
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permeability [42–44]. AQP1 protein is strongly expressed 
in human and animal models of highly proliferating 
microvessels [43] and the chick embryo chorioallantoic 
membrane [44]. In human retinal epithelial cells, osmotic 
stress decreases AQP4 expression [45]. Reduction in 
AQP1 expression by targeted siRNA inhibits hyperos-
molarity-dependent angiogenesis. In general, angiogen-
esis requires endothelial cell proliferation, adhesion and 
migration. We found a significant decrease in network 
number and areas in AQP1-silenced cultures, indicating 
a lost capacity to organize tubuli in networks. This is in 
line with previous reports showing that AQP1 plays a key 
role in endothelial cell migration, an early fundamental 
step in angiogenesis [10, 46].
Data from the present study also provide a mechanis-
tic explanation on how AQP1 is linked to endothelial cell 
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migration and tubulization. We observed that high glu-
cose, at levels of 30.5 mmol/L, corresponding to 450 mg/
dL, a plasma level possibly found in uncontrolled diabe-
tes—increases COX-2 expression. This effect is in part 
dependent on the hyperosmolar component of hyper-
glycemia, since mimicked by the exposure of cells to 
the metabolically inactive monosaccharides mannitol or 
l-glucose.
TonEBP/NFAT5, a rel/NF-κB family member, has been 
identified as a transcription factor that in response to 
hyperosmolarity activates the transcription of osmo-
sensing genes, including aldose reductase and protein 
kinase C delta [47], TNF-α and monocyte chemoat-
tractant protein (MCP)-1 [30, 34–36]. In renal medul-
lary epithelial cells, hypertonic stress increased COX-2 
promoter activity in a luciferase reporter assay [37, 48]. 
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Also, hypertonic saline had been reported to induce 
COX-2 in rat macrophages [49] and HUVECs [50], but 
in experimental conditions that do not reproduce the 
diabetic milieu. The participation of NFAT transcription 
factors in the activation of COX-2 expression had also 
been already demonstrated in several cell types [31, 32, 
51–54]. Indeed, previous research had shown that the 
angiogenic signaling involved in the induction of COX-2 
by vascular endothelial growth factor (VEGF) in human 
endothelial cells requires the activation of NFAT proteins 
[51, 55]. Furthermore, TonEBP/NFAT5 is required for the 
hypertonic induction of COX-2 in renal epithelial cells 
[31]. An upregulation of the NFAT-MMP-2 pathway had 
been also demonstrated in the development of metastatic 
osteosarcoma, where the secretion of active MMP-2 is 
under the transcriptional regulation of NFAT [32]. Here 
however we provide the first evidence that the induction 
of COX-2 in endothelial cells is largely hyperosmolarity-
related, and that TonEBP/NFAT5 is here involved, since 
(a) TonEBP/NFAT total abundance was increased in cells 
exposed to high glucose or high mannitol; (b) EMSA and 
Western analysis demonstrated a cytoplasm-to-nucleus 
redistribution of TonEBP/NFAT in endothelial cells; and 
(c) TonEBP/NFAT gene disruption prevented hyperos-
molarity-related induction of COX-2. Of note, our data 
show that at least another signal transduction pathways 
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Fig. 6 Retinal neovascularization and higher expression of AQP1 and COX‑2 in the Ins2Akita mice. a, b Upper panels: Hematoxylin/eosin‑stained 
retinal cross‑sections from sex‑ and age‑matched (1 year‑old) C57BL/6 non‑diabetic control mice (a) and D2.B6‑Ins2 Akita (b). Magnification: 60x. 
Lower panels: immunohistochemistry of CD31‑stained retinal cross‑sections from D2.B6‑Ins2 Akita (a) and sex‑ and age‑matched (1 year‑old) 
C57BL/6 non‑diabetic control mice (b), showing higher CD31 immunoreactivity in the D2.B6‑Ins2 Akita mice. Magnification: 40x and 100x. c The 
extent of angiogenesis was determined by measuring total vessels (arterioles and capillaries) density in light microscopy sections. N = 2 eyes per 
animal, with each experimental group consisting of n = 7 mice. The bar graph represents for each value the mean ± S.D. from 3 separate experi‑
ments. **, P < 0.01 vs C57BL/6 control mice. d, e: Western analysis of COX‑2 and AQP1 expression in retinas from D2.B6‑Ins2 Akita mouse and from 
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consisting of n = 7 mice. The bar graph represents for each value the mean ± S.D. from three separate experiments. **, P < 0.01 vs C57BL/6 control 
mice
Page 11 of 14Madonna et al. Cardiovasc Diabetol  (2016) 15:18 
Fig. 7 The involvement of AQP1 in retinal neovascularization in the Ins2Akita and C57BL/6 mice. Immunofluorescence staining of retinal cross‑sec‑
tions for α‑smooth muscle actin (ASMA) and 4′,6‑diamidino‑2‑phenylindole (DAPI) for nuclei from D2.B6‑Ins2 Akita (G‑N) and sex‑ and age‑matched 
(1 year‑old) C57BL/6 non‑diabetic control mice (a–f), after intravitreal injection of saline (sham, panels a, b g, h), or siRNA with scrambled sequence 
(siRNA‑scr, panels c, d, i, l) or siRNA against AQP1 (siRNA‑AQP1, panels e, f, n, m). Magnification: 10x
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activated by high glucose, but with lesser relevance to 
COX-2 expression and angiogenesis, such as the NF-κB 
pathway, is—conversely—not substantially induced by 
high mannitol, indicating a larger dependence of NF-κB 
activation on metabolic effects of glucose.
A number of studies have shown that hyperosmolarity 
(as tested by high mannitol) does not influence angio-
genesis and/or COX-2 expression in endothelial cells 
[55, 56]. Culture conditions used in these studies may 
not reflect those used in our study. Our data show more 
robust effects when using glucose concentrations as high 
as 50.5  mM, or with lower concentrations but for pro-
longed times, which may more closely mimic diabetic 
pathophysiology. Concentrations of glucose outside the 
range tested here might exert different effects, therefore 
not completely ruling out the additional involvement 
of mechanisms different from hyperosmolarity. Never-
theless, our data clearly indicate that hyperosmolarity 
is an important part of the mechanisms through which 
chronic exposure to high glucose may promote angiogen-
esis and cardiovascular complications of diabetes.
We recognize some limitations of our study. Main ones 
are that (a) there is limited translability of murine data to 
humans; (b) molecular mechanisms by which TonEBP/
NFAT operates on the COX-2 promoter are still incom-
pletely understood; (c) we still need to close the circle of 
the in  vivo causality demonstration involving the tran-
scription factor TonEBP/NFAT5 as an additional osmo-
signaling effector by showing that the in vivo interruption 
of the TonEBP signaling mitigates the in  vivo increased 
angiogenesis in response to high glucose. Such experi-
ments are complicated by the lack of available transgenic 
mouse models of TonEBP knockouts. Such limitations 
might however be overcome in the future through the 
prolonged administration of drugs targeting TonEBP 
activation.
Nonetheless, data provided here lend support to the 
hypothesis that hyperosmolarity is an important mecha-
nism of vascular disease in diabetes and a potential tar-
get for future therapies, with several potential practical 
implications. In principle, promotion of inflammation 
and angiogenesis by COX-2 through a hyperosmolarity-
related mechanism may have a role not only in micro-
vascular disease (proliferative retinopathy), as shown 
here, but also in macrovascular disease (e.g., plaque rup-
ture), both increased in diabetes. The unraveling of the 
hyperosmolarity-related signaling, as sketched in Fig.  9, 
pointing both to the sensing molecule AQP1 and the 
effector molecule COX-2, allows identifying potential 
pharmacological targets to reduce hyperosmolar stress-
related excessive angiogenesis. In addition, the in  vivo 
expressions of AQP1 and COX-2 might serve as new 
markers for diabetic complications. The in vivo implica-
tions of these observations are therefore worth further 
assessment.
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Fig. 9 A scheme of the putative signaling pathway through which 
hyperosmotic stress contributes to some of the vascular events in 
diabetes, based on findings from the present study. In the plasma 
membrane, hyperglycemia activates “osmosensing” structures, such 
as aquaporin (AQP)‑1, which can sense osmolarity changes; and an 
“osmosignaling” pathway, involving the transcription factor tonic‑
ity enhancer binding protein (Ton/EBP), which can transmit the 
signal towards effector regulatory sites in the nuclei, able to further 
promote the expression of proinflammatory genes such as adhesion 
molecules and cycloxygenase (COX)‑2
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